Davis Spotlights HDA's 2021 Strategic Priorities

January 05, 2021
HDA will be carrying forward the early lessons learned from COVID-19 pandemic and supporting response efforts in 2021, writes President and CEO Chip Davis in the January 4 issue of Chain Drug Review — particularly as distributors play a role in the largest public vaccination effort in recent memory. Davis provided his perspective on the year ahead, along with other healthcare trade association leaders, as part of the publication’s 2021 “Pharmacy Outlook” feature.

“From a healthcare delivery perspective, the logistics expertise of our industry has never been more relied upon, and scrutinized, than it is today,” writes Davis. “As the calendar turns to 2021, eradicating COVID-19 will depend on a supply chain that is moving forward — safely, securely and efficiently. Collaborative relationships, among healthcare stakeholders and between the public and private sectors, also will continue to be critical to ensuring much-needed treatments and medical supplies reach the right place at the right time.”

Given the increased focus on how products move through the healthcare supply chain, Davis notes that HDA will work to ensure that the role and value of distribution is known and understood by federal and state policymakers. To that end, the Alliance will advocate on behalf of its members on such priority issues as healthcare affordability, supply chain resiliency, prescription drug abuse and pharmaceutical traceability implementation.

Read the column.